Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart devices track cancer recovery at home

NCT ID NCT04501913

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if patients could use the devices and if the data helped staff spot problems early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

22 people

The number who actually took part.

Started

Dec 2019

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cancer patients diagnosed with gastrointestinal, genitourinary, or gynecological cancers who are scheduled to undergo abdominal/pelvic surgery at the City of Hope National Medical Center

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cancer patients diagnosed with GI (esophagus, gastric, colorectal, hepatobiliary) GU (prostate, bladder, renal cell), or GYN (ovarian, endometrial, cervical) cancers * Patients who are scheduled to undergo major abdominal/pelvic surgery for cancer treatment * Ability to read and understand English * We are targeting patients across all stages of disease * All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical stage 0 esophageal adenocarcinoma ajcc V8 Clinical stage 0 esophageal squamous cell carcinoma ajcc V8 Clinical stage 0 gastric cancer ajcc V8 Clinical stage I esophageal adenocarcinoma ajcc V8 Clinical stage I esophageal squamous cell carcinoma ajcc V8 Clinical stage I gastric cancer ajcc V8 Clinical stage II esophageal adenocarcinoma ajcc V8 Clinical stage II esophageal squamous cell carcinoma ajcc V8 Clinical stage II gastric cancer ajcc V8 Clinical stage IIA esophageal adenocarcinoma ajcc V8 Clinical stage IIA gastric cancer ajcc V8 Clinical stage IIB esophageal adenocarcinoma ajcc V8 Clinical stage IIB gastric cancer ajcc V8 Clinical stage III esophageal adenocarcinoma ajcc V8 Clinical stage III esophageal squamous cell carcinoma ajcc V8 Clinical stage III gastric cancer ajcc V8 Clinical stage IV esophageal adenocarcinoma ajcc V8 Clinical stage IV esophageal squamous cell carcinoma ajcc V8 Clinical stage IV gastric cancer ajcc V8 Clinical stage IVA esophageal adenocarcinoma ajcc V8 Clinical stage IVA esophageal squamous cell carcinoma ajcc V8 Clinical stage IVA gastric cancer ajcc V8 Clinical stage IVB esophageal adenocarcinoma ajcc V8 Clinical stage IVB esophageal squamous cell carcinoma ajcc V8 Clinical stage IVB gastric cancer ajcc V8 Hepatobiliary neoplasm Malignant digestive system neoplasm Malignant female reproductive system neoplasm Malignant genitourinary system neoplasm Malignant neoplasm Pathologic stage 0 esophageal adenocarcinoma ajcc V8 Pathologic stage 0 esophageal squamous cell carcinoma ajcc V8 Pathologic stage 0 gastric cancer ajcc V8 Pathologic stage I esophageal adenocarcinoma ajcc V8 Pathologic stage I esophageal squamous cell carcinoma ajcc V8 Pathologic stage I gastric cancer ajcc V8 Pathologic stage IA esophageal adenocarcinoma ajcc V8 Pathologic stage IA esophageal squamous cell carcinoma ajcc V8 Pathologic stage IA gastric cancer ajcc V8 Pathologic stage IB esophageal adenocarcinoma ajcc V8 Pathologic stage IB esophageal squamous cell carcinoma ajcc V8 Pathologic stage IB gastric cancer ajcc V8 Pathologic stage IC esophageal adenocarcinoma ajcc V8 Pathologic stage II esophageal adenocarcinoma ajcc V8 Pathologic stage II esophageal squamous cell carcinoma ajcc V8 Pathologic stage II gastric cancer ajcc V8 Pathologic stage IIA esophageal adenocarcinoma ajcc V8 Pathologic stage IIA esophageal squamous cell carcinoma ajcc V8 Pathologic stage IIA gastric cancer ajcc V8 Pathologic stage IIB esophageal adenocarcinoma ajcc V8 Pathologic stage IIB esophageal squamous cell carcinoma ajcc V8 Pathologic stage IIB gastric cancer ajcc V8 Pathologic stage III esophageal adenocarcinoma ajcc V8 Pathologic stage III esophageal squamous cell carcinoma ajcc V8 Pathologic stage III gastric cancer ajcc V8 Pathologic stage IIIA esophageal adenocarcinoma ajcc V8 Pathologic stage IIIA esophageal squamous cell carcinoma ajcc V8 Pathologic stage IIIA gastric cancer ajcc V8 Pathologic stage IIIB esophageal adenocarcinoma ajcc V8 Pathologic stage IIIB esophageal squamous cell carcinoma ajcc V8 Pathologic stage IIIB gastric cancer ajcc V8 Pathologic stage IIIC gastric cancer ajcc V8 Pathologic stage IV esophageal adenocarcinoma ajcc V8 Pathologic stage IV esophageal squamous cell carcinoma ajcc V8 Pathologic stage IV gastric cancer ajcc V8 Pathologic stage IVA esophageal adenocarcinoma ajcc V8 Pathologic stage IVA esophageal squamous cell carcinoma ajcc V8 Pathologic stage IVB esophageal adenocarcinoma ajcc V8 Pathologic stage IVB esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage I esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage I esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage II esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage II esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage III esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage III esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage IIIA esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage IIIA esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage IIIB esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage IIIB esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage IV esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage IV esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage IVA esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage IVA esophageal squamous cell carcinoma ajcc V8 Postneoadjuvant therapy stage IVB esophageal adenocarcinoma ajcc V8 Postneoadjuvant therapy stage IVB esophageal squamous cell carcinoma ajcc V8 Stage 0 colorectal cancer ajcc V8 Stage 0A bladder cancer ajcc V8 Stage 0IS bladder cancer ajcc V8 Stage I bladder cancer ajcc V8 Stage I cervical cancer ajcc V8 Stage I colorectal cancer ajcc V8 Stage I ovarian cancer ajcc V8 Stage I prostate cancer ajcc V8 Stage I renal cell cancer ajcc V8 Stage I uterine corpus cancer ajcc V8 Stage IA cervical cancer ajcc V8 Stage IA ovarian cancer ajcc V8 Stage IA uterine corpus cancer ajcc V8 Stage IA1 cervical cancer ajcc V8 Stage IA2 cervical cancer ajcc V8 Stage IB cervical cancer ajcc V8 Stage IB ovarian cancer ajcc V8 Stage IB uterine corpus cancer ajcc V8 Stage IB1 cervical cancer ajcc V8 Stage IB2 cervical cancer ajcc V8 Stage IC ovarian cancer ajcc V8 Stage II bladder cancer ajcc V8 Stage II cervical cancer ajcc V8 Stage II colorectal cancer ajcc V8 Stage II ovarian cancer ajcc V8 Stage II prostate cancer ajcc V8 Stage II renal cell cancer ajcc V8 Stage II uterine corpus cancer ajcc V8 Stage IIA cervical cancer ajcc V8 Stage IIA colorectal cancer ajcc V8 Stage IIA ovarian cancer ajcc V8 Stage IIA prostate cancer ajcc V8 Stage IIA1 cervical cancer ajcc V8 Stage IIA2 cervical cancer ajcc V8 Stage IIB cervical cancer ajcc V8 Stage IIB colorectal cancer ajcc V8 Stage IIB ovarian cancer ajcc V8 Stage IIB prostate cancer ajcc V8 Stage IIC colorectal cancer ajcc V8 Stage IIC prostate cancer ajcc V8 Stage III bladder cancer ajcc V8 Stage III cervical cancer ajcc V8 Stage III colorectal cancer ajcc V8 Stage III ovarian cancer ajcc V8 Stage III prostate cancer ajcc V8 Stage III renal cell cancer ajcc V8 Stage III uterine corpus cancer ajcc V8 Stage IIIA bladder cancer ajcc V8 Stage IIIA cervical cancer ajcc V8 Stage IIIA colorectal cancer ajcc V8 Stage IIIA ovarian cancer ajcc V8 Stage IIIA prostate cancer ajcc V8 Stage IIIA uterine corpus cancer ajcc V8 Stage IIIA1 ovarian cancer ajcc V8 Stage IIIA2 ovarian cancer ajcc V8 Stage IIIB bladder cancer ajcc V8 Stage IIIB cervical cancer ajcc V8 Stage IIIB colorectal cancer ajcc V8 Stage IIIB ovarian cancer ajcc V8 Stage IIIB prostate cancer ajcc V8 Stage IIIB uterine corpus cancer ajcc V8 Stage IIIC colorectal cancer ajcc V8 Stage IIIC ovarian cancer ajcc V8 Stage IIIC prostate cancer ajcc V8 Stage IIIC uterine corpus cancer ajcc V8 Stage IIIC1 uterine corpus cancer ajcc V8 Stage IIIC2 uterine corpus cancer ajcc V8 Stage IV bladder cancer ajcc V8 Stage IV cervical cancer ajcc V8 Stage IV colorectal cancer ajcc V8 Stage IV ovarian cancer ajcc V8 Stage IV prostate cancer ajcc V8 Stage IV renal cell cancer ajcc V8 Stage IV uterine corpus cancer ajcc V8 Stage IVA bladder cancer ajcc V8 Stage IVA cervical cancer ajcc V8 Stage IVA colorectal cancer ajcc V8 Stage IVA ovarian cancer ajcc V8 Stage IVA prostate cancer ajcc V8 Stage IVA uterine corpus cancer ajcc V8 Stage IVB bladder cancer ajcc V8 Stage IVB cervical cancer ajcc V8 Stage IVB colorectal cancer ajcc V8 Stage IVB ovarian cancer ajcc V8 Stage IVB prostate cancer ajcc V8 Stage IVB uterine corpus cancer ajcc V8 Stage IVC colorectal cancer ajcc V8

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.